Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Silo Pharma Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
SILO
Nasdaq
8731
https://silopharma.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Silo Pharma Inc
Silo Pharma Announces Positive Results for Intranasal PTSD Treatment
- Apr 23rd, 2024 12:15 pm
Silo Pharma set to Acquire Exclusive Licensing for Promising Alzheimer’s Disease Therapeutic
- Apr 10th, 2024 12:11 pm
Silo Pharma Exercises Option for Exclusive License Agreement for First-in-Class PTSD and Stress-Induced Anxiety Therapeutic
- Mar 20th, 2024 12:30 pm
Silo Pharma Files Patent for Groundbreaking Ketamine Implant Therapeutic to Target Fibromyalgia and Chronic Pain
- Mar 18th, 2024 11:15 am
Silo Pharma Completes Successful Dose-Ranging Study of SPC-15 Intranasal Therapeutic for PTSD
- Feb 28th, 2024 1:25 pm
Silo Pharma’s SP-26 Ketamine Implant Demonstrates Successful Drug Delivery
- Feb 14th, 2024 1:45 pm
Silo Pharma Announces Pipeline Prioritization for 2024 Targeting Mental Health, Chronic Pain, and Neurology
- Feb 1st, 2024 3:00 pm
Silo Pharma Announces Positive Results in Alzheimer’s Disease Study
- Jan 24th, 2024 1:55 pm
Silo Pharma Successfully Completes First Phase of Dose-Ranging Study of SPC-15 an Intranasal Treatment for PTSD
- Jan 4th, 2024 1:55 pm
Silo Pharma and Partner Receive Regulatory Approval to Begin Development of Ketamine Implant for Fibromyalgia
- Dec 28th, 2023 1:25 pm
Silo Pharma Enters into Exclusive License Agreement with Medspray Pharma BV for Intranasal Technology used in SPC-15 Treatment for PTSD
- Nov 21st, 2023 1:01 pm
Silo Pharma to Initiate Dose-Ranging Study of Novel Intranasal Therapeutic SPC-15 for the Treatment of PTSD
- Nov 8th, 2023 1:11 pm
Silo Pharma’s SPU-21 Peptide Shows Positive Results Against Rheumatoid Arthritis
- Oct 16th, 2023 12:11 pm
Silo Pharma Initiates Human Factor Study of SPC-15 for the Treatment of PTSD
- Oct 11th, 2023 12:35 pm
Silo Pharma Announces Positive Data on SPC-15 for PTSD and Prepares to File Pre-Investigational New Drug (IND) Application with FDA
- Sep 20th, 2023 12:28 pm
Silo Pharma Initiates Feasibility Study of SPC-15 Novel Intranasal Formulation for PTSD
- Sep 12th, 2023 12:50 pm
Silo Pharma Engages Clarivate for Intellectual Property and Patent Management
- Aug 10th, 2023 12:50 pm
Silo Pharma Reaches Positive Milestone with Nasal Formulation of SPC-15 For Anxiety, PTSD, and Stress-Related Disorders
- Aug 8th, 2023 12:30 pm
Psychedelics Company Silo Pharma Working On Time-Release And Dosage Ketamine Implant And Topical, Hoping To Deliver Steady Pain Relief For Four Million Fibromyalgia Sufferers
- Jun 23rd, 2023 1:00 pm
Silo Pharma’s SPU-21 Treatment for Autoimmune Disease Awarded U.S. Patent
- Jun 21st, 2023 1:00 pm
Scroll